We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


Intradigm Licences Key Delivery Intellectual Property in the field of RNAi from Massachusetts Institute of Technology

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Intradigm Licences Key Delivery Intellectual Property in the field of RNAi from Massachusetts Institute of Technology"

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Read time:

Intradigm Corporation has announced that it has licensed a key patent related to nucleic acid delivery technologies in the field of RNAi drug development from Massachusetts Institute of Technology (MIT).

According to Intradigm, the licensing of this intellectual property strengthens Intradigm's RNAi delivery platform patent portfolio. The scope of the licensed technology covers a broad range of biodegradable polymer structures for the delivery of RNAi therapeutics, thus increasing the opportunity to achieve successful clinical proof of concept.

The licensed technology also allows Intradigm to pursue applications for its RNAi NanoPlex™ technology across a wider range of therapeutic indications.

"Intradigm's licensing of this RNAi delivery technology intellectual property is consistent with our commitment to establish a strong IP position that will allow us to identify, develop and commercialize optimal delivery platforms toward the ultimate realization of RNAi therapeutics. This transaction builds on our dominant IP position in the field of biodegradable polymers delivery platform for RNAi therapeutics," said Mohammad Azab, M.D., president and chief executive officer of Intradigm.

"We believe that our licensing of this important intellectual property demonstrates that Intradigm is a key player in the space. We are thrilled to continue our work in the exciting area of RNAi therapeutic development with these new resources at our disposal."